Primary Epstein-Barr virus infection

Journal of Clinical Virology - Tập 102 - Trang 84-92 - 2018
Samantha K. Dunmire1, Priya S. Verghese2, Henry H. Balfour1,2
1Department of Laboratory Medicine and Pathology, USA
2Department of Pediatrics, University of Minnesota Medical Center, Minneapolis, MN 55455, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

de-The, 1975, Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study – a review, IARC Sci. Publ., 3

Epstein, 1964, Cultivation in vitro of human lymphoblasts from Burkitt's malignant lymphoma, Lancet, 1, 252, 10.1016/S0140-6736(64)92354-2

Epstein, 1964, Virus particles in cultured lymphoblasts from Burkitt's lymphoma, Lancet, 1, 702, 10.1016/S0140-6736(64)91524-7

Epstein, 1965, Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt's lymphoma, J. Exp. Med., 121, 761, 10.1084/jem.121.5.761

Hjalgrim, 2003, Characteristics of Hodgkin's lymphoma after infectious mononucleosis, N. Engl. J. Med., 349, 1324, 10.1056/NEJMoa023141

Old, 1966, Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells, Proc. Natl. Acad. Sci. U.S.A., 56, 1699, 10.1073/pnas.56.6.1699

zur Hausen, 1970, EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx, Nature, 228, 1056, 10.1038/2281056a0

Shibata, 1991, Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma, Am. J. Pathol., 139, 469

Thorley-Lawson, 2004, Persistence of the Epstein-Barr virus and the origins of associated lymphomas, N. Engl. J. Med., 350, 1328, 10.1056/NEJMra032015

Ascherio, 2012, The initiation and prevention of multiple sclerosis, Nat. Rev. Neurol., 8, 602, 10.1038/nrneurol.2012.198

Henle, 1967, Immunofluorescence, interference, and complement fixation technics in the detection of the herpes-type virus in Burkitt tumor cell lines, Cancer Res., 27, 2442

Levin, 2010, Primary infection with the Epstein-Barr virus and risk of multiple sclerosis, Ann. Neurol., 67, 824

Balfour, 2013, Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6–19 years in the United States and factors affecting its acquisition, J. Infect. Dis., 208, 1286, 10.1093/infdis/jit321

Venkitaraman, 1985, The seroepidemiology of infection due to Epstein-Barr virus in southern India, J. Med. Virol., 15, 11, 10.1002/jmv.1890150103

Condon, 2014, Age-specific prevalence of Epstein-Barr virus infection among Minnesota children: effects of race/ethnicity and family environment, Clin. Infect. Dis., 59, 501, 10.1093/cid/ciu342

Balfour, 2013, Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students, J. Infect. Dis., 207, 80, 10.1093/infdis/jis646

Grimm, 2016, Prospective studies of infectious mononucleosis in university students, Clin. Transl. Immunol., 5, e94, 10.1038/cti.2016.48

Morris, 2002, The changing epidemiology of infectious mononucleosis, J. Infect., 45, 107, 10.1053/jinf.2002.1022

Takeuchi, 2006, Prevalence of Epstein-Barr virus in Japan: trends and future prediction, Pathol. Int., 56, 112, 10.1111/j.1440-1827.2006.01936.x

Evans, 1968, Seroepidemiologic studies of infectious mononucleosis with EB virus, N. Engl. J. Med., 279, 1121, 10.1056/NEJM196811212792101

Lehane, 1970, A seroepidemiologic study of infectious mononucleosis: the development of EB virus antibody in a military population, JAMA, 212, 2240, 10.1001/jama.1970.03170260036009

1971, A Infectious mononucleosis and its relationship to EB virus antibody. A joint investigation by university health physicians and P.H.L.S. laboratories, Br. Med. J., 4, 643, 10.1136/bmj.4.5788.643

Sawyer, 1971, Prospective studies of a group of Yale University freshmen: I. Occurrence of infectious mononucleosis, J. Infect. Dis., 123, 263, 10.1093/infdis/123.3.263

Hallee, 1974, Infectious mononucleosis at the United States Military Academy: a prospective study of a single class over four years, Yale J. Biol. Med., 47, 182

Dan, 1990, A prospective study of primary Epstein-Barr virus infections among university students in Hong Kong, Am. J. Trop. Med. Hyg., 42, 380, 10.4269/ajtmh.1990.42.380

Piriou, 2012, Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma, J. Infect. Dis., 205, 906, 10.1093/infdis/jir872

Slyker, 2013, Clinical and virologic manifestations of primary Epstein-Barr virus (EBV) infection in Kenyan infants born to HIV-infected women, J. Infect. Dis., 207, 1798, 10.1093/infdis/jit093

Melbye, 1984, Infectious mononucleosis in Greenland: a disease of the non-indigenous population, Scand. J. Infect. Dis., 16, 9, 10.3109/00365548409068403

Banwell, 2007, Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study, Lancet Neurol., 6, 773, 10.1016/S1474-4422(07)70196-5

Krabbe, 1981, Primary Epstein-Barr virus infection in early childhood, Arch. Dis. Child., 56, 49, 10.1136/adc.56.1.49

Jayasooriya, 2015, Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children, PLoS Pathog., 11, e1004746, 10.1371/journal.ppat.1004746

Gantt, 2016, Prospective characterization of the risk factors for transmission and symptoms of primary human herpesvirus infections among Ugandan infants, J. Infect. Dis., 214, 36, 10.1093/infdis/jiw076

Balfour, 2013, Primary Epstein-Barr virus infection: impact of age at acquisition, coinfection, and viral load, J. Infect. Dis., 207, 1787, 10.1093/infdis/jit096

Hoagland, 1955, The transmission of infectious mononucleosis, Am. J. Med. Sci., 229, 262, 10.1097/00000441-195503000-00003

Crawford, 2006, A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis, Clin. Infect. Dis., 43, 276, 10.1086/505400

Gerber, 1969, Association of EB-virus infection with the post-perfusion syndrome, Lancet, 1, 593, 10.1016/S0140-6736(69)91532-3

Alfieri, 1996, Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx, Blood, 87, 812, 10.1182/blood.V87.2.812.bloodjournal872812

Trottier, 2012, Transfusion-related Epstein-Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children, Transfusion (Paris), 52, 2653, 10.1111/j.1537-2995.2012.03611.x

Shapiro, 1988, Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation, Blood, 71, 1234, 10.1182/blood.V71.5.1234.bloodjournal7151234

Verghese, 2015, Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation, Transplantation, 99, 1186, 10.1097/TP.0000000000000490

Sumaya, 1986, Epstein-Barr virus infections in families: the role of children with infectious mononucleosis, J. Infect. Dis., 154, 842, 10.1093/infdis/154.5.842

Johnson, 2016, Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study, Clin. Transl. Immunol., 5, e81, 10.1038/cti.2016.28

Lang, 1977, Early acquisition of cytomegalovirus and Epstein-Barr virus antibody in several isolated Melanesian populations, Am. J. Epidemiol., 105, 480, 10.1093/oxfordjournals.aje.a112407

Butler, 2010, A population-based study of how children are exposed to saliva in KwaZulu-Natal Province, South Africa: implications for the spread of saliva-borne pathogens to children, Trop. Med. Int. Health., 15, 442

Svedmyr, 1984, Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis, Clin. Immunol. Immunopathol., 30, 437, 10.1016/0090-1229(84)90029-1

Balfour, 2005, A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis, J. Infect. Dis., 192, 1505, 10.1086/491740

Balfour, 1972, Penicillin-related exanthems in infectious mononucleosis identical to those associated with ampicillin, Clin. Pediatr. (Phila.), 11, 417, 10.1177/000992287201100711

Horwitz, 1981, Clinical and laboratory evaluation of infants and children with Epstein-Barr virus-induced infectious mononucleosis: report of 32 patients (aged 10–48 months), Blood, 57, 933, 10.1182/blood.V57.5.933.bloodjournal575933

White, 1985, Review of the clinical manifestations, laboratory findings, and complications of infectious mononucleosis, Wis. Med. J., 84, 19

Connelly, 1994, Neurologic complications of infectious mononucleosis, Pediatr. Neurol., 10, 181, 10.1016/0887-8994(94)90021-3

Jenson, 2000, Acute complications of Epstein-Barr virus infectious mononucleosis, Curr. Opin. Pediatr., 12, 263, 10.1097/00008480-200006000-00016

Hoagland, 1957, Splenic rupture in infectious mononucleosis, Ann. Intern. Med., 46, 1184, 10.7326/0003-4819-46-6-1184

Putukian, 2008, Mononucleosis and athletic participation: an evidence-based subject review, Clin. J. Sport Med., 18, 309, 10.1097/JSM.0b013e31817e34f8

Iaria, 2008, Acute acalculous cholecystitis during the course of primary Epstein-Barr virus infection: a new case and a review of the literature, Int. J. Infect. Dis., 12, 391, 10.1016/j.ijid.2007.10.005

Burnard, 2017, EBV and MS: Major cause, minor contribution or red-herring?, Mult. Scler. Relat. Disord., 16, 24, 10.1016/j.msard.2017.06.002

Hwang, 2012, Evidence of genetic susceptibility to infectious mononucleosis: a twin study, Epidemiol. Infect., 140, 2089, 10.1017/S0950268811002457

Rostgaard, 2014, A genetic basis for infectious mononucleosis: evidence from a family study of hospitalized cases in Denmark, Clin. Infect. Dis., 58, 1684, 10.1093/cid/ciu204

Chandran, 2007, Gammaherpesviruses entry and early events during infection

Hutt-Fletcher, 2007, Epstein-Barr virus entry, J. Virol., 81, 7825, 10.1128/JVI.00445-07

Thorley-Lawson, 2001, Epstein-Barr virus: exploiting the immune system, Nat. Rev. Immunol., 1, 75, 10.1038/35095584

Young, 2007, EBV gene expression and regulation

Rowe, 1987, Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells, EMBO J., 6, 2743, 10.1002/j.1460-2075.1987.tb02568.x

Dunmire, 2015, The incubation period of primary Epstein-Barr virus infection: viral dynamics and immunologic events, PLoS Pathog., 11, e1005286, 10.1371/journal.ppat.1005286

Hutt-Fletcher, 2017, The long and complicated relationship between Epstein-Barr virus and epithelial cells, J. Virol., 91, 7825, 10.1128/JVI.01677-16

Hochberg, 2004, Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells, J. Virol., 78, 5194, 10.1128/JVI.78.10.5194-5204.2004

Summers, 1976, Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid, J. Virol., 18, 151, 10.1128/JVI.18.1.151-155.1976

Sugden, 1979, Epstein-Barr virus DNA is amplified in transformed lymphocytes, J. Virol., 31, 590, 10.1128/JVI.31.3.590-595.1979

Sample, 1990, Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes, J. Virol., 64, 4084, 10.1128/JVI.64.9.4084-4092.1990

Puchhammer-Stockl, 2006, Cytomegalovirus and Epstein-Barr virus subtypes–the search for clinical significance, J. Clin. Virol., 36, 239, 10.1016/j.jcv.2006.03.004

Dunmire, 2014, Primary EBV infection induces an expression profile distinct from other viruses but similar to hemophagocytic syndromes, PLoS One, 9, e85422, 10.1371/journal.pone.0085422

Panikkar, 2015, Cytokine-mediated loss of blood dendritic cells during Epstein-Barr virus-associated acute infectious mononucleosis: implication for immune dysregulation, J. Infect. Dis., 212, 1957, 10.1093/infdis/jiv340

Albanese, 2017, MicroRNAs of Epstein-Barr virus control innate and adaptive antiviral immunity, J. Virol., 91, e01667, 10.1128/JVI.01667-16

Hooykaas, 2017, EBV MicroRNA BART16 suppresses type I IFN signaling, J. Immunol., 198, 4062, 10.4049/jimmunol.1501605

Hendricks, 2014, Cutting edge: NKG2C(hi)CD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus, J. Immunol., 192, 4492, 10.4049/jimmunol.1303211

Azzi, 2014, Role for early-differentiated natural killer cells in infectious mononucleosis, Blood, 124, 2533, 10.1182/blood-2014-01-553024

Chijioke, 2013, Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection, Cell. Rep., 5, 1489, 10.1016/j.celrep.2013.11.041

Hayday, 2000, Gammadelta cells and the regulation of mucosal immune responses, Am. J. Respir. Crit. Care Med., 162, S161, 10.1164/ajrccm.162.supplement_3.15tac4

Born, 2006, The function of gammadelta T cells in innate immunity, Curr. Opin. Immunol., 18, 31, 10.1016/j.coi.2005.11.007

Djaoud, 2017, Two alternate strategies for innate immunity to Epstein-Barr virus: one using NK cells and the other NK cells and gammadelta T cells, J. Exp. Med., 214, 1827, 10.1084/jem.20161017

Hislop, 2007, Cellular responses to viral infection in humans: lessons from Epstein-Barr virus, Annu. Rev. Immunol., 25, 587, 10.1146/annurev.immunol.25.022106.141553

Long, 2013, MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response, J. Exp. Med., 210, 933, 10.1084/jem.20121437

Paul, 1932, The presence of heterophile antibodies in infectious mononucleosis, Am. J. Med. Sci., 183, 90, 10.1097/00000441-193201000-00010

Horwitz, 1979, Persistent falsely positive rapid tests for infectious mononucleosis. Report of five cases with four–six-year follow-up data, Am. J. Clin. Pathol., 72, 807, 10.1093/ajcp/72.5.807

Fisher, 2004, False-positive result provided by rapid heterophile antibody test in a case of acute infection with hepatitis E virus, J. Clin. Microbiol., 42, 4411, 10.1128/JCM.42.9.4411.2004

Blake, 1976, Measurement of heterophil antibody and antibodies to EB viral capsid antigen IgG and IgM in suspected cases of infectious mononucleosis, J. Clin. Pathol., 29, 841, 10.1136/jcp.29.9.841

Guerrero-Ramos, 2014, Performance of the architect EBV antibody panel for determination of Epstein-Barr virus infection stage in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosis, Clin. Vaccine Immunol., 21, 817, 10.1128/CVI.00754-13

Bauer, 2001, Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology, Clin. Lab., 47, 223

Hodson, 2005, Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials, Lancet, 365, 2105, 10.1016/S0140-6736(05)66553-1

Kalil, 2005, Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients, Ann. Intern. Med., 143, 870, 10.7326/0003-4819-143-12-200512200-00005

Humar, 2006, A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder, Transplantation, 81, 856, 10.1097/01.tp.0000202724.07714.a2

Smith, 2007, Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients, Transplantation, 83, 1423, 10.1097/01.tp.0000265914.16491.7d

Gu, 1995, First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen, Dev. Biol. Stand., 84, 171

Maurer, 2003, Smallpox vaccine: contraindications, administration, and adverse reactions, Am. Fam. Physician, 68, 889

Jackman, 1999, Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine, Vaccine, 17, 660, 10.1016/S0264-410X(98)00248-5

Servat, 2015, Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo, Vaccine, 33, 6771, 10.1016/j.vaccine.2015.10.024

Moutschen, 2007, Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults, Vaccine, 25, 4697, 10.1016/j.vaccine.2007.04.008

Sokal, 2007, Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults, J. Infect. Dis., 196, 1749, 10.1086/523813

Rees, 2009, A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation, Transplantation, 88, 1025, 10.1097/TP.0b013e3181b9d918

Elliott, 2008, Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis, J. Virol., 82, 1448, 10.1128/JVI.01409-07

Candy, 2006, Steroids for symptom control in infectious mononucleosis (review), Cochrane Database Syst. Rev., 3, CD004402

Romain, 2010, A method for evaluating antiviral drug susceptibility of Epstein-Barr virus, Virus Adapt. Treat., 2, 1

Balfour, 2007, A virologic pilot study of valacyclovir for infectious mononucleosis, J. Clin. Virol., 39, 16, 10.1016/j.jcv.2007.02.002

Dharnidharka, 2018, Comprehensive review of post-organ transplant hematologic cancers, Am. J. Transplant., 18, 537, 10.1111/ajt.14603

Verghese, 2015, The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study, Transplantation, 99, 602, 10.1097/TP.0000000000000354

Harris, 2000, The world health organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997, Mod. Pathol., 13, 193, 10.1038/modpathol.3880035

Johnson, 2006, Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis, Am. J. Transplant., 6, 2743, 10.1111/j.1600-6143.2006.01543.x

Holman, 2012, Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder, Clin. Transplant., 26, 741, 10.1111/j.1399-0012.2012.01608.x

AlDabbagh, 2017, The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review, Am. J. Transplant., 17, 770, 10.1111/ajt.14020